Cocrystal Pharma Advances Promising Influenza A Drug

Cocrystal Pharma Inc (COCP) has issued an update.

Cocrystal Pharma, Inc. has announced progress in the clinical development of their CC-42344 drug candidate, which shows promise as a treatment for both pandemic and seasonal influenza A. The update was shared in a recent press release by the company.

For a thorough assessment of COCP stock, go to TipRanks’ Stock Analysis page.